|
APONTIS PHARMA AG / Key word(s): Change in Forecast/Profit Warning APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 27-Jul-2023 / 22:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014 APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 Monheim am Rhein, 27 July 2023. APONTIS PHARMA AG (“APONTIS PHARMA” or “Company“, Ticker APPH / ISIN DE000A3CMGM5) has withdrawn today its forecast for fiscal year 2023 and with it also its medium-term planning for 2026 based on preliminary figures for the first half of 2023 and expectations for the second half of the year. The reason for this is a slower growth of the Single Pill business than initially expected. Furthermore, expenses related to the resignation of former CEO Karlheinz Gast will lead to an additional cost burden. A forecast for fiscal year 2023 cannot yet be issued at the present time. To improve profitability in the coming years, the Company has begun preparing a program to increase operational performance and efficiency. This will involve evaluating strategic options for sales and marketing activities to increase sales on the one hand and measures to improve cost structures on the other. The Company will report regularly on the progress of the program. The Company will publish its 2023 half-year report as planned on 10 August 2023. APONTIS PHARMA AG Investor Relations APONTIS PHARMA press contact CROSS ALLIANCE End of Inside Information 27-Jul-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Personalized phage therapy successfully treats antibiotic-resistant infections in animals
A new study demonstrates an advance in treating antibiotic-resistant infections in animals through personalized phage therapy.
May 27, 2024